Department of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, C-233A LSRC Bldg., P.O. Box 3813, Durham, NC, 27710, USA.
Cell Commun Signal. 2021 May 22;19(1):59. doi: 10.1186/s12964-021-00739-6.
The ABL kinases, ABL1 and ABL2, promote tumor progression and metastasis in various solid tumors. Recent reports have shown that ABL kinases have increased expression and/or activity in solid tumors and that ABL inactivation impairs metastasis. The therapeutic effects of ABL inactivation are due in part to ABL-dependent regulation of diverse cellular processes related to the epithelial to mesenchymal transition and subsequent steps in the metastatic cascade. ABL kinases target multiple signaling pathways required for promoting one or more steps in the metastatic cascade. These findings highlight the potential utility of specific ABL kinase inhibitors as a novel treatment paradigm for patients with advanced metastatic disease. Video abstract.
ABL 激酶(ABL1 和 ABL2)促进多种实体瘤的肿瘤进展和转移。最近的报告表明,ABL 激酶在实体瘤中的表达和/或活性增加,并且 ABL 失活会损害转移。ABL 失活的治疗效果部分归因于 ABL 依赖性调节与上皮间质转化和转移级联的后续步骤相关的多种细胞过程。ABL 激酶靶向促进转移级联的一个或多个步骤所需的多种信号通路。这些发现突出了特定 ABL 激酶抑制剂作为晚期转移性疾病患者新的治疗范例的潜力。视频摘要。